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INTRODUCTION
Neovascular age-related macular degeneration (AMD) is a leading 
cause of legal blindness in the elderly.1,2 There are a number of rea-
sons for vision loss, but the most common involve compromise of 
the retinal pigment epithelial (RPE) barrier integrity, activation of 
choroidal endothelial cells (CECs) to migrate across the RPE mono-
layer into the sensory retina, and the development of choroidal 
neovascularization (CNV). The RPE monolayer creates the “outer 
blood retinal barrier”, but with aging and other stresses, the barrier 
integrity of the RPE monolayer becomes compromised.3 RPE bar-
rier integrity requires integration of junctional proteins that make 
up adherens and tight junctions.4 The junctional protein complex 
of the RPE barrier disassembles with physiologic stresses and can 
be restored.5 However, with repeated insults, crosstalk  between 
signaling pathways, or overwhelming pathologic stresses, barrier 
compromise occurs.6 There is evidence that RPE barrier integrity is 
necessary to contain angiogenic growth factors and fluid from the 
choroidal vasculature beneath the basal aspect of the RPE mono-
layer7 and restrict CEC transmigration8 into the sensory retina, 
whereas reduced RPE barrier integrity is speculated to allow growth 
factor and fluid movement and facilitate CEC transmigration into 
the sensory retina.9 Clinical studies support the line of thinking that 
RPE barrier integrity reduces vision loss from neovascular AMD.10 
Therefore, a means to maintain or restore RPE barrier integrity may 
prevent or reduce vision loss from neovascular AMD.
Rap1 is a GTPase of the Ras superfamily that is important in cell 
junction maintenance11 and motility.12 Rap1 has two isoforms, Rap1a 
and Rap1b, which are encoded on different chromosomes but have 
95% homology.13 For either Rap1 isoform to cause a biologic event, 
the GTPase must be activated by a guanine nucleotide exchange 
factor (GEF), stimulating the binding of GTP and subsequent activa-
tion of downstream effector proteins. A GTPase-activating protein 
(GAP) then renders the GTPase inactive by aiding the intrinsic rate 
of hydrolysis of GTP back to GDP. Thus, Rap1 isoforms act as biologic 
switches, cycling between active and inactive forms. In cultured RPE 
cells, activation of each isoform increased RPE junctional integrity by 
different mechanisms. Rap1a restricted RPE junction disassembly, 
whereas Rap1b facilitated junctional reassembly.9 The mechanism 
of the effect of Rap1a involved interference with the assembly of 
NADPH oxidase subunits and with NADPH oxidase-generated reac-
tive oxygen species (ROS). NADPH oxidase-generated ROS phos-
phorylate cadherins and disrupt adherens junctional complexes 
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To test the hypothesis that increased Rap1a activity specifically in retinal pigment epithelial cells resists choroidal neovasculariza-
tion (CNV), self-complementary adeno-associated virus 2 (scAAV2) with RPE65-promoter-driven GFP vectors were generated and 
introduced subretinally into Rap1b-deficient mice. Six-week-old mice that received subretinal control (scAAV2-Con) or constitu-
tively active Rap1a (scAAV2-CARap1a) showed strong GFP at the 5 × 108 viral particle/µl dose 5 weeks later without altering retinal 
morphology or function. Compared to scAAV2-Con- or phosphate-buffered saline (PBS)-injected, eyes injected with scAAV2-CAR-
ap1a had increased Rap1 in retinal pigment epithelial (RPE)/choroidal lysates and a significant reduction in CNV volume 7 days after 
laser, comparable to eyes that received intravitreal anti-VEGF versus IgG control. scAAV2-CARap1a-, but not anti-VEGF-, injected 
eyes had increased  pan-cadherin in RPE/choroids. In cultured RPE cells, increased active Rap1a inhibited TNFα-induced disas-
sociation of junctional pan-cadherin/β-catenin complexes, increased transepithelial electrical resistance through an interaction 
of β-catenin with phosphorylated scaffold protein, IQGAP1, and inhibited choroidal endothelial cell (CEC) transmigration of an RPE 
monolayer. This  evidence shows that increased Rap1a activity specifically in RPE cells is sufficient to reduce CEC transmigration and 
CNV and involves IQGAP1-mediated protection of RPE junctional complexes.
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of the RPE monolayer.14 Rap1a interacted with NADPH oxidase 
subunit, p22phox, and prevented the interaction of p22phox with 
other subunits needed to activate NADPH oxidase.14 Active Rap1a 
also reduced CEC transmigration of an RPE monolayer.14 Therefore, 
activation of Rap1a in cultured RPE cells limited pathologic events 
that are important in the development of neovascular AMD. Since 
Rap1b is involved in angiogenesis,15,16 activation of both isoforms 
might stimulate angiogenesis through active Rap1b and be coun-
terproductive in restricting CNV through active Rap1a, depending 
on the prevalence and activation of Rap1 isoforms.
In this study, we tested the hypothesis that active Rap1a intro-
duced specifically into RPE cells would resist laser induced CNV in 
an in vivo model and probed the mechanisms involved in the activa-
tion of Rap1a on RPE barrier integrity.
ReSUlTS
Generation of self-complementary adeno-associated virus 2 (scAAV2) 
driven by RPE65 promoter to deliver active Rap1a to RPE cells
To address the hypothesis that activation of Rap1a specifically in 
RPE cells would reduce the formation of CNV in vivo, we first gen-
erated self-complementary adeno-associated virus 2 (scAAV2) with 
a green fluorescent protein (GFP) tag, which contains a murine 
RPE65 promoter that specifically targets RPE cells (kindly provided 
by T. Michael Redmond, PhD). A synthetic coding sequence for the 
point mutation, constitutively active human Rap1a Q63E mutant 
(CARap1a)17 was later cloned into the scAAV2 as pscAAV2-RPE65-
CARap1a-GFP, and the scAAV2 vector driving GFP only (pscAAV2-
RPE65-GFP) was used as a control vector (Figure 1a). The active 
Rap1a amino acid sequences of murine and human are identical. To 
test RPE cell-specific targeting of scAAV2 vectors, scAAV2 plasmid 
DNAs expressing GFP or CARap1a were transfected into ARPE-19, a 
cell line of human RPE cells, or human retinal microvascular endo-
thelial cells (hRMVECs), and expression of GFP was used to assess 
plasmid DNA expression. As shown in Figure 1b, GFP was visualized 
in ARPE-19 cells, but not hRMVECs, indicating that scAAV2 vectors 
driven by the RPE65 promoter specifically targeted RPE cells in vitro. 
Although the promoter was a murine RPE65, it can drive some GFP 
expression in human cells (T. Michael Redmond, personal commu-
nication, 2016).
In vivo analysis of scAAV2 transduction and Rap1 expression in 
RPE cells and the effect of scAAV2 on retinal structure and visual 
function
We next determined whether the scAAV2 viral vectors efficiently 
and specifically targeted RPE cells in vivo. Plasmid DNA scAAV2-
RPE65-CARap1a-GFP or scAAV2-RPE65-GFP was used to produce 
experimental or control scAAV2 virus, named scAAV2-CARap1a or 
scAAV2-Con, respectively. Either scAAV2-CARap1a or scAAV2-Con at 
different doses was administered via subretinal injection into both 
eyes of 6-week-old wild-type C57Bl/6 mice (WT) mice. An injection 
caused a transient retinal detachment that affected about a third of 
the posterior eye and enabled transduction of RPE. An additional 
group of mice received bilateral subretinal injections of PBS as a 
control for the scAAV2 viral injections. Viral transduction was moni-
tored by GFP expression using the Micron IV retinal imaging system 
weekly from week 2 to week 5. As shown in Figure 2, both scAAV2-
CARap1a and scAAV2-Con at 5 × 108 viral particles (vp)/µl) showed 
viral transduction by visualization of GFP at week 5 after subretinal 
injections, whereas PBS-injected eyes showed no GFP (Figure 2a). As 
further confirmation of viral transduction, GFP-positive eyes were 
harvested, and RPE/choroidal cryosections were immunostained for 
GFP. GFP colocalized with RPE65-labeled RPE cells (Figure 2b). Also, 
there was increased Rap1 protein in RPE/choroidal lysates from 
scAAV2-CARap1a at the 5 × 108 vp/µl dose compared to scAAV2-Con 
or PBS injection (Figure 2c).
To then determine if the dose affected the structure or visual 
function of the retina, optical coherence tomography (OCT) and 
focal electroretinography (fERG) were performed. At the points of 
injection in all groups, there were changes in retinal structure with 
loss of the inner segment/outer segment lines and photorecep-
tors (Figure 2d, upper row). Outside the injection site but within 
the regions where subretinal injections of scAAV2-CARap1a or 
scAAV2-Con had been delivered 5 weeks earlier, there were no mor-
phological differences noted by OCT (Figure 2d, lower row). No dif-
ferences in retinal structure by OCT were noted between GFP+ or 
GFP- regions within the same eyes (Figure 2d, upper and lower rows, 
respectively). There were also no differences in retinal structure in 
PBS-, scAAV2-Con, or scAAV-CARap1a (Figure 2e) or in amplitudes of 
a-waves and b-waves by fERG (Figure 2f ). Therefore, both scAAV2s 
effectively and safely transduced RPE cells 5 weeks after subreti-
nal injections, and scAAV2-CARap1a increased RPE Rap1 protein 
Figure 1 Generation of self-complementary adeno-associated virus 2 
(scAAV2) to deliver constitutively active Rap1a (CARap1a) driven by an 
RPE65 promoter to retinal pigment epithelial (RPE) cells. (a) Diagrams 
of the scAAV2 containing the RPE cell-specific RPE65 promoter driving 
GFP (control vector scAAV2-RPE65-GFP) or CARap1a (scAAV2-RPE65-
CARap1a-GFP); (b) images taken under fluorescent microcopy showing 
GFP expression in a cell line of human RPE cells, ARPE-19, but not 
in human retinal microvascular endothelial cells (hRMVECs), each 
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compared to scAAV2-Con. Therefore, these conditions were used in 
subsequent experiments.
Expression of active Rap1a in RPE cells reduces CNV in Rap1b-
deficient mice
As Rap1b is implicated in promoting VEGF/VEGFR2-mediated angio-
genesis,15,16 which is important in neovascular AMD,18,19 we restricted 
activation of Rap1 to only the Rap1a isoform by using Rap1b-/- mice. 
We previously published that activation of Rap1a with the chemical, 
8-CPT-2Me-cAMP, delivered as an intravitreal injection, reduced CNV 
in Rap1b-/- mice.14 However, here we wished to focus on the hypoth-
esis that activation of Rap1a specifically in RPE cells would inhibit CNV 
and wished to eliminate effects from activation of Rap1a in CECs or 
other cells. We, therefore, introduced activated Rap1a specifically into 
RPE cells by subretinal injection of scAAV2-CARap1a and compared 
outcomes to scAAV2-Con or PBS-injected eyes. Five weeks after sub-
retinal injections of scAAV2 vectors or PBS, Rap1b-/- and Rap1b+/- mice 
were treated with laser to induce CNV. As shown in Figure 3a, four laser 
spots were distributed in the retina, each about 2 disc diameters from 
the optic nerve. One week after laser treatment, eyes were harvested 
for RPE/choroidal flat mounts, and isolectin-stained CNV spots within 
regions of GFP-positive RPE cells were analyzed for CNV volume (Figure 
3b). As shown in Figure 3c,d, eyes injected with scAAV2-CARap1a had 
significantly reduced CNV volume with 60% reduction in Rap1b-/-
 (Figure 3c) and 40% reduction in Rap1b+/- mice (Figure 3d) compared 
to either PBS or scAAV2-Con injections. There was no significant effect 
on CNV of scAAV2-CARap1a injected into Rap1b+/+ mice compared to 
scAAV2-Con or PBS in part due variability of CNV lesions, potentially 
due to different isoform dominance and activation (data not shown). 
scAAV2-CARap1a did not increase apoptosis either within CNV lesions 
or in the retina overlying the CNV lesions compared to eyes that had 
been injected with either PBS or scAAV2-Con (data not shown). As a 
comparison reflecting the current standard of care for neovascular 
AMD, an intravitreal injection of a neutralizing antibody against mouse 
VEGF164, the most prevalent VEGF splice variant, was delivered into 
both eyes of a separate group of 11-week-old Rap1b+/- mice immedi-
ately after laser treatment and compared to similar Rap1b+/- mice that 
received intravitreal control isotype IgG. One week later, CNV volumes 
analyzed in isolectin stained RPE/choroidal flatmounts (Figure 3e) 
showed that anti-VEGF caused a 36% reduction in CNV volume com-
pared to IgG control (Figure 3f), comparable to the effects seen from 
activation of Rap1a specifically in RPE cells in Rap1b+/- mice.
Figure 2 In vivo analysis of scAAV2 transduction in RPE cells of mice injected with scAAV2 vectors at dose of 5 × 108 viral particle/µl. (a) Micron IV retinal 
imaging of GFP and (b) Immunostaining of GFP or isotype IgG and RPE65 in retinal/ retinal pigment epithelial (RPE)/choroidal cryosections in scAAV2 
or PBS-injected wild type mice; (c) western blots of Rap1 protein in RPE/choroids from scAAV2 or PBS injected Rap1b+/- mice; (d) Optical coherence 
tomography (OCT) of retinal structure and morphology directed by Micron IV retinal imaging; (e) OCTs through regions of previous subretinal injections 
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Expression of active Rap1a in RPE cells has no effect on VEGF-
mediated signaling, but increases junctional cadherins in RPE/
choroids
VEGF signaling plays an important role in human neovascular 
AMD.18,19 Since the fold decrease in CNV volume in scAAV2-CAR-
ap1a versus scAAV2-Con was comparable to that from intravit-
real anti-VEGF versus IgG, we wished to determine if activation of 
Rap1a affected VEGF expression or signaling. We previously found 
that laser-induced CNV increased NADPH oxidase-generated 
ROS in CNV20 and VEGF protein in RPE/choroidal lysates in wild-
type C57Bl/6 mice.21 By western blot analysis, VEGF protein and 
phosphorylation of ERK (p-ERK), a downstream signaling effector 
of  activated VEGFR2, were measured in RPE/choroids from PBS, 
scAAV2-Con- or scAAV2-CARap1a-treated and lasered Rap1b+/-
 mice. There were no differences in VEGF protein concentration 
(Figure 4a,b) or p-ERK1/2 (Y204) (Figure 4c,d) in RPE/choroids 
among any groups. In the same tissue lysates, however, the junc-
tional cadherin proteins were significantly increased by scAAV2-
CARap1a compared to scAAV2-Con treatment (Figure 4e,f ). We 
used a pan-cadherin antibody to identify both E-cadherin, which 
is generally more abundant in epithelial cells, and also N-cadherin, 
which is more abundant in RPE cells.22
Expression of active Rap1a maintains RPE barrier function 
following TNFα stimulation through an IQGAP1-mediated 
interaction with β-catenin
We23 and others24 reported that TNFα contributes to CNV induced 
by laser in murine eyes, at least in part, by activating NADPH oxi-
dase in RPE cells.23 We now wanted to know if this TNFα-induced 
ROS generation provoked RPE barrier compromise. RPE barrier 
integrity was determined two ways: formation of junctional pan-
cadherin/β-catenin complexes by coimmunoprecipitation (CO-
IP) and electric cell-substrate impedance sensing (ECIS) analysis. 
Human RPE cells were cultured until a monolayer was formed. Cells 
were then exposed to PBS or TNFα (20 ng/ml) overnight. H2O2 (10 
µmol/l) was used as a positive control.14 Compared to PBS, TNFα 
decreased CO-IP of pan-cadherin/β-catenin to a similar level as 
H2O2; however, the β-catenin protein in cell lysates was not reduced 
by either TNFα or H2O2 treatment (Figure 5a). In a parallel experi-
ment, RPE cells were plated into electrode coated ECIS culture-ware 
Figure 3 Expression of active Rap1a in RPE cells reduces choroidal neovascularization (CNV) in Rap1b deficient mice. (a) Micron IV imaging of laser spots 
in the retina of mice in the laser-induced CNV model; (b) Images of retinal pigment epithelial (RPE)/choroidal flat mounts stained with isolectin and 
anti-GFP antibody and normalized CNV volume (fold change over scAAV2-Con) in (c) Rap1b-/- and (d) Rap1b+/- mice treated with subretinal injections 
of PBS, control virus scAAV2-Con or scAAV2-CARap1a virus at 5X108 vp/µl (*P < 0.05, **P < 0.01 versus scAAV2-Con; †††P<0.001 versus PBS); (e) Images 
of RPE/choroidal flat mounts stained with isolectin and (f) normalized CNV volume (fold change over IgG) of Rap1b+/- mice treated with intravitreal 
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and maintained until electrical resistance of RPE cells was stabilized. 
Human RPE cells were then exposed to TNFα or PBS overnight, and 
resistance was monitored. As shown in Figure 5b, compared to PBS, 
electrical resistance of RPE cells started to decrease 1 hour after cells 
were exposed to TNFα and was maximally reduced after 5 hours of 
TNFα-incubation (Figure 5b).
We next studied the mechanism involved in TNFα-mediated 
reduced RPE barrier resistance. We are interested in the multi-
domain scaffold protein, IQGAP1, which regulates cell adhesion and 
cell motility by interacting with F-actin, cadherins and β-catenin.25–28 
In the unphosphorylated or unbound state, IQGAP1 does not play 
a role in many signaling events. However, when phosphorylated, 
IQGAP1 can facilitate pathologic signaling.29 A role of IQGAP1 in 
enhancing barrier function has been proposed;30,31 however, its role 
in RPE barrier integrity is unknown. We hypothesized that the inter-
action between IQGAP1 and β-catenin facilitated junctional cad-
herin proteins and β-catenin association, and thereby maintained 
barrier integrity of the RPE cells. To test this hypothesis, CO-IP of 
IQGAP1 and β-catenin was performed in RPE cells treated with TNFα 
vs. control. As shown in Figure 5c,d, after 5 hours of TNFα exposure, 
CO-IP of IQGAP1 and β-catenin was significantly decreased. This 
decreased interaction of β-catenin with IQGAP1 was not a result of 
reduced β-catenin in RPE cells, as β-catenin protein was increased 
in RPE cells treated with TNFα (Figure 3d), a finding consistent with 
our previous study.21 In the same lysates, there was increased ser-
ine/threonine phosphorylation of IQGAP1. As a further confirma-
tion, RPE barrier integrity was assessed by CO-IP of pan-cadherin 
and β-catenin in RPE cells transfected with IQGAP1 siRNA or con-
trol siRNA and treated with TNFα. As shown in Figure 5e,f, in con-
trol siRNA-transfected RPE cells, compared to PBS, TNFα treatment 
significantly decreased CO-IP of β-catenin and pan-cadherin, analo-
gous to that seen in Figure 5a. However, the decreased interaction 
of β-catenin and pan-cadherin induced by TNFα treatment was not 
seen in RPE cells knocked down for IQGAP1 when compared to con-
trol siRNA (Figure 5f ). Neither TNFα treatment nor IQGAP1 knock-
down affected pan-cadherin protein levels in RPE cells. Altogether, 
the data shown in Figure 5 suggest that TNFα reduces RPE barrier 
integrity through a mechanism involving IQGAP1 phosphorylation 
and interaction with β-catenin.
We previously reported that activation of Rap1 increases RPE 
barrier integrity.9,14 We found TNFα also reduced active Rap1 in 
human RPE cells (Figure 6a). To increase active Rap1a, cultured RPE 
Figure 4 Expression of active Rap1a in RPE cells has no effect on VEGF, but increases junctional protein, cadherin, in RPE/choroids. Western blots 
of (a and b) VEGF protein, (c and d) phosphorylation of ERK1/2 (p-ERK1/2) and (e and f) pan-cadherin in retinal pigment epithelial (RPE)/choroids 
from Rap1b+/- mice treated with subretinal injection of PBS, scAAV2-Con or scAAV2-CARap1a (a, c and e are representative gels and b, d and f are 
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cells were transduced with adenovirus expressing the Rap1a Q63E 
mutant that constitutively activates Rap1a (Ad-63E) or adenovirus 
expressing only GFP (Ad-GFP) as a control. Forty-eight hours after 
viral transduction, RPE cells were exposed to PBS or TNFα for 5 hours 
and CO-IP of β-catenin and cadherin was determined in RPE cells. As 
shown in Figure 6b,c, compared to Ad-GFP and PBS treatment, RPE 
cells transduced with Ad-63E had significantly increased CO-IP of 
β-catenin and pan-cadherin, suggesting greater structural integrity 
of the junctions. In Ad-GFP-transduced RPE cells, TNFα treatment 
significantly decreased CO-IP of β-catenin and pan-cadherin, and 
this reduction was significantly inhibited by active Rap1a in RPE 
cells transduced with Ad-63E (Figure 6c). Ad-63E also increased 
cadherin protein level (Figure 6b), similar to that seen in RPE/cho-
roids from mouse eyes treated with scAAV2-CARap1a (Figure 4e,f ). 
Furthermore, the reduced CO-IP of IQGAP1/β-catenin (Figure 6d,e), 
and increased phosphorylation of IQGAP1 from TNFα treatment 
(Figure 6d,f ) were inhibited by Ad-63E transduction. Altogether, 
the results support the line of thinking that active Rap1a maintains 
RPE barrier integrity after exposure to TNFα by modulating the 
interaction between IQGAP1 and β-catenin in a phosphorylation- 
dependent mechanism.
We also determined the effect of active Rap1a on RPE barrier 
function by measuring transepithelial electrical resistance (TER) in 
the presence of increased active Rap1a compared to control. TERs 
of human RPE monolayers transduced with Ad-GFP and Ad-63E 
were measured prior to and following overnight treatment with 
TNFα, and the differences in TER were then calculated. As shown in 
Figure 6g, TNFα mediated a reduction in TER that was inhibited in 
Ad-63E-transduced RPE cells compared to Ad-GFP, suggesting that 
active Rap1a was sufficient to protect against RPE barrier compro-
mise from TNFα exposure. Finally, we also found that expression of 
active Rap1a in Ad-63E-transduced RPE cells was sufficient to inhibit 
Figure 5 TNFα reduces RPE barrier integrity by a mechanism involving IQGAP1 interaction with β-catenin and phosphorylation. 
(a)  Co-immunoprecipitation of junctional protein pan-cadherin and β-catenin and western blots of β-catenin and β-actin in retinal pigment 
epithelial (RPE) cells exposed to PBS, H2O2 (10 µmol/l), or human recombinant TNFα (20 ng/ml) overnight; (b) Electric Cell-substrate Impedance 
Sensing (ECIS) analysis of barrier resistance of RPE cells exposed to human recombinant TNFα (10 or 20 ng/ml) or control PBS for 12 hours; (c) and 
(d) coimmunoprecipitation of IQGAP1 and β-catenin or phosphorylation of IQGAP1 and western blots of β-catenin and β-actin in RPE cells exposed to 
TNFα (20 ng/ml) or control PBS for 5 hours (c, representative gel images and d, quantification of densitometry of C; ***P < 0.001 versus PBS of IQGAP1/β-
catenin; †††P < 0.001 versus PBS of p-IQGAP1; ‡‡P < 0.01 versus PBS of β-catenin) and (e) and (f) coimmunoprecipitation of β-catenin and pan-cadherin 
and western blot of IQGAP1 and pan-cadherin in RPE cells transfected with IQGAP1 siRNA or control siRNA and treated with TNFα (20 ng/ml) or control 
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CEC transmigration in the human RPE cell-CEC transmigration assay 
(Figure 6h).
DISCUSSION
Intact RPE barrier integrity is important for the health and function of 
the retinal photoreceptors and choriocapillaris.32 In neovascular AMD, 
severe vision loss occurs when the RPE barrier is compromised and 
when activated CECs are able to migrate across the RPE monolayer 
into the sensory retina and develop into leaky CNV. Increasing RPE 
barrier integrity may be one way to prevent or reduce CNV. We previ-
ously reported that activation of the Rap1a and 1b isoforms enhance 
RPE barrier integrity in different ways.9,14 However, active Rap1b also 
induces angiogenesis,15 so broad activation of both, closely related, iso-
forms may be counterproductive, depending on the prevalence and 
activation of Rap1 isoforms, when attempting to inhibit CNV. We also 
previously reported that activation of Rap1a in Rap1b-/- mice by injec-
tion of intravitreal 8-CPT-2Me-cAMP reduced CNV.14 Here, we wished 
to test the hypothesis that activation of Rap1a specifically in RPE cells 
would enhance RPE barrier integrity and be sufficient to reduce CNV.
To increase Rap1a activity in RPE cells, a constitutively active 
Rap1a mutant was engineered into a self-complementary adeno-
associated virus 2 vector with a GFP tag driven by a murine RPE65 
promoter and was shown to specifically target the RPE cells 
(Figure 1b). In vivo Micron IV live imaging demonstrated GFP expres-
sion after injection of 5 × 108 vp/µl showing effective transduction 
of the mouse RPE cells at 5 weeks after subretinal administration. 
Western blots confirmed that scAAV2-CARap1a increased Rap1 
protein level in RPE cells compared to scAAV2-Con. In wild-type 
C57Bl/6 mice, subretinal injections of scAAV2-Rap1a did not reduce 
CNV compared to controls. This may have been in part due to inabil-
ity to control for variable expression and state of activation of each 
isoform in wild type RPE cells. Our in vitro data supported the role 
of active Rap1a in reducing NADPH oxidase-generated ROS in RPE 
cells and in improving RPE barrier integrity.14 We speculate that 
Rap1b is abundantly expressed in mice and may mask the effects 
from introducing constitutively active Rap1a. For example, Rap1b-
/- produce larger CNV following laser injury than did Rap1b+/+.9 
Therefore, to eliminate Rap1b, we used Rap1b-/- mice to test the 
effects of increased active Rap1a specifically in RPE cells. We also 
Figure 6 Expression of active Rap1a in RPE cells reduces cell barrier compromise from TNFα by modulating IQGAP1 interactions with β-catenin and 
IQGAP1 phosphorylation. Rap1 activity assay in (a) retinal pigment epithelial (RPE) cells exposed to PBS, H2O2 (10 µmol/l), or human recombinant 
TNFα (20 ng/ml) overnight and (b) and (c) coimmunoprecipitation of β-catenin and pan-cadherin and western blot of pan-cadherin (b, representative 
gel images and c, quantification of densitometry of b; fold change over Ad-GFP/PBS) and (d–f) coimmunoprecipitation of IQGAP1 and β-catenin and 
phosphorylation of IQGAP1 in RPE cells transduced with Ad-GFP or Ad-63E and treated with PBS or TNFα (20 ng/ml) for 5 hours (d, representative gel 
images and e and f, quantification of densitometry of d) (g) Transepithelial resistance (TER) and (h) normalized CEC transmigration (fold change over 
Ad-GFP/PBS) of RPE cells transduced with Ad-GFP or Ad-63E and treated with PBS or TNFα (20 ng/ml) for 24 hours (*P < 0.05, **P < 0.01 and ***P < 0.001 
versus Ad-GFP/PBS; †P < 0.05, ††P < 0.01 and †††P < 0.001 versus Ad-GFP/TNFα and ‡‡‡P < 0.001 versus Ad-63E/PBS).
PBS H2O2 TNFα
PBS TNFα PBS TNFα
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treated Rap1b+/- mice, anticipating the heterozygote with some 
Rap1b in all cells might have a reduced inhibitory effect on CNV 
from active Rap1a, because Rap1b is involved in angiogenesis.15 
We found that scAAV2-CARap1a significantly reduced CNV in both 
Rap1b-/- and Rap1b+/- mice with a greater fold decrease in the homo-
zygous knockout mice treated with scAAV2-CARap1a compared to 
control scAAV2-Con, supporting this hypothesis. The introduction 
of CARap1a specifically into RPE reduced CNV in the Rap1b null 
mice but not in wild-type mice. We are pursuing the hypotheses 
that dominance of isoforms and relative ratio of activated vs. inacti-
vated isoforms differs across species and tissues to partially account 
for this. It may also be that Rap1a activation in CECs in addition to 
activation in RPE is needed to fully interfere with CNV.33
scAAV2-CARap1a did not increase retinal apoptosis. Compared 
to PBS, ocular injections of either of scAAV2 vectors did not cause 
adverse effects on retinal morphology determined by OCT imag-
ing or visual function by focal ERG. Taken together, these results 
support the line of thinking that increased Rap1a in RPE cells can 
effectively reduce CNV, and ocular injection of scAAV2 driven by an 
RPE65 promoter can efficiently target the RPE cells without causing 
structural or functional deficits of the retina.
Since both inflammatory and angiogenic pathways are important 
in the development of neovascular AMD,34–36 ligands from each can 
act to cause a feed-forward loop to overwhelm homeostasis and 
enable CEC migration and transmigration of the RPE cells,6 an essen-
tial step in the formation of CNV in the sensory retina in neovascular 
AMD.10 We previously reported that the proinflammatory cytokine, 
TNFα, was increased in RPE/choroids from mice that were treated 
with laser to induce CNV.21 Here, we determined that TNFα reduced 
RPE barrier resistance, as evidenced by decreased junctional pan-
cadherin/β-catenin complexes and transepithelial resistance. TNFα-
induced RPE barrier compromise was associated with decreased 
interaction of junctional protein β-catenin with the scaffold pro-
tein, IQGAP1. IQGAP1 is a multidomain protein that is believed to 
integrate multiple intracellular signaling pathways involved in cell 
adhesion and cell motility by interacting with partner proteins.37 At 
its RasGAP-like C-terminal binding domain, IQGAP1 interacts with 
cadherin proteins and β-catenin. Therefore, we tested the hypoth-
esis that IQGAP1 facilitated the formation of junctional protein com-
plexes involving cadherins and β-catenin, and, thereby, protected 
RPE barrier compromise from TNFα. We found that knockdown of 
IQGAP1 by siRNA transfection in RPE cells reduced cadherin and 
β-catenin complexes but also inhibited the TNFα-induced decrease 
in cadherin and β-catenin complexes. This suggested that when 
IQGAP1 is unphosphorylated, it interacts with β-catenin and brings 
together β-catenin and cadherin for RPE junctional integrity. TNFα-
induced phosphorylation of IQGAP1 interferes with interactions 
between β-catenin and cadherins, which are involved in RPE junc-
tional function. We further found that increased active Rap1a in RPE 
cells inhibited TNFα-mediated reduction in cadherin and β-catenin 
complexes and IQGAP1 and β-catenin interactions. These find-
ings were associated with increased TER, reduced TNFα-induced 
IQGAP1 phosphorylation, and reduced CEC transmigration of the 
RPE monolayer.
We previously reported that VEGF protein was increased in RPE 
cell/choroids from wild type C57Bl/6 mice treated with laser 7 days 
earlier.21 Here, however, in the condition of partial knockdown of 
Rap1b, we did not find that scAAV2-CARap1a modulated VEGF or 
VEGF signaling compared to scAAV2-Con in Rap1b heterozygous 
knockout mice. Repeated delivery of anti-VEGF agents by intravit-
real injection is the standard of care for neovascular AMD. However, 
clinical studies show that this anti-VEGF treatment improves out-
comes in only about 40% of cases.1 In addition to potential compli-
cations from repeated intravitreal injection, there are also concerns 
that concomitant removal of the beneficial effects of VEGF will 
potentiate atrophy of the choriocapillaris and retinal elements in 
AMD patients.38,39 Therefore, a means to increase RPE barrier integ-
rity, potentially by regulating active Rap1, may improve outcomes 
in neovascular AMD and reduce the number of anti-VEGF injections.
In summary, we generated scAAV2 vectors to deliver active Rap1a 
that targeted and increased Rap1a in RPE cells. The data provide evi-
dence for the first time that increased active Rap1a specifically in the 
RPE layer can effectively increase RPE barrier integrity and reduce 
laser-induced CNV in Rap1b deficient mice without adverse effects on 
retinal structure and function. We also present a novel mechanism by 
which activated Rap1a specifically in RPE cells can counteract TNFα-
induced RPE barrier compromise by regulating the phosphorylation 
of the scaffold protein, IQGAP1, and its interaction with the junctional 
protein β-catenin. Currently, effective inhibition of CNV by active 
Rap1a in RPE is seen in Rap1b null mice. More study is warranted.
MATeRIAlS AND MeTHODS
Animals
Rap1b-/-, Rap1b+/- and littermate wild-type mice were generated as described 
previously.40 Six- to 12-week-old mice were used in these studies. All animal 
procedures were performed in accordance with the University of Utah guide-
lines (Guide for the Care and Use of Laboratory Animals) and the Association 
for Research in Vision and Ophthalmology Statement for the Use of Animals 
in Ophthalmic and Vision Research. Anesthesia was obtained with ketamine 
(100 mg/kg) and xylazine (20 mg/kg), and euthanasia was performed under 
CO2 exposure. All efforts were made to minimize suffering.
Construction of RPE-65 promoter driven self-complementary 
adeno-associated virus 2
A self-complementary adeno-associated virus 2 (scAAV2) vector was pur-
chased from University of North Carolina Vector Core (Chapel Hill, NC). The 
scAAV2 vectors contain sequences for GFP. The CMV promoter was replaced 
with a murine RPE65 promotor (kindly provided by T. Michael Redwood), 
and synthetic sequence for constitutively active human Rap1a Q63E mutant 
(CARap1a) was then cloned into the scAAV2 vector with the RPE65 promoter 
(scAAV2-RPE65-CARap1a-GFP). The scAAV2 construct without CARap1a was 
used as a control vector (scAAV2-RPE65-GFP). Sequences of plasmid DNAs, 
scAAV2-RPE-65-CARap1a-GFP and scAAV2-RPE65-GFP were confirmed by 
DNA sequencing (HSC Core Facility at University of Utah, Salt Lake City, UT). 
Viruses were produced, purified and titered at the UNC Vector Core.
Ocular injections, micron IV imaging, optical coherence 
tomography, focal electroretinography and laser-induced CNV 
model
One microliter containing scAAV2 at 5 × 108 viral particles or PBS was injected 
into the subretinal space of each eye of 6-week-old mice. The scAAV2 viral 
transduction was monitored by in vivo live imaging using the Micron IV reti-
nal imaging system (Phoenix Research Laboratories, Pleasanton, CA) under 
a GFP filter. Image-guided spectral domain coherence tomography (OCT, 
Phoenix Labs, Manchester, CT) was used to visualize retinal structure and 
morphology after AAV2 viral injections.
Four weeks after scAAV2 vector injection, retinal function was assessed 
by image guided focal electroretinogram (fERG) using Micron IV technology. 
Mice were fully dark adapted overnight and subsequently handled under 
dim red light illumination. After anesthesia and pupil dilation with tropi-
camide (1%) eye drops (Bausch and Lomb, Tampa, FL), mice were kept on 
a heat pad throughout the procedure to maintain constant body tempera-
ture. Subdermal needle electrodes were inserted underneath the skin at the 
base of the tail (ground electrode) and between the eyes on the forehead 
(reference electrode). Corneas were lubricated with coupling gel (GenTeal, 
hypromellose 0.3%, Alcon, Fort Worth, TX), the objective/electrode was 
advanced near the corneal surface, deep red illumination was used to focus 
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on the retina and an unlasered retinal section of 0.25 mm diameter (spot size 
A) was chosen. Responses to focal light stimuli were elicited at luminances 
ranging from 1.1 to 3.8 cd s m−2 with 30 sweeps at 2 seconds intervals. Data 
is displayed as the mean amplitude (in µV) of the a-wave (as a measure of 
photoreceptor function) and b-wave (as a measure of bipolar cell function).
Five weeks after AAV2 viral injection, 11-week-old mice received laser to 
induce CNV. Both eyes of each mouse were dilated with one drop of 1% trop-
icamide ophthalmic solution. After dilation, mice were anesthetized, placed 
onto a heated stage and treated with 4–5 spots of 532 nm laser photocoagu-
lation each about 2 disc diameters from the optic nerve with the Phoenix 
Image-Guided Laser System 94 (Phoenix Micron IV, Pleasanton, CA) at set-
tings of ~400 mW intensity and 100 ms duration. Adequate treatment was 
assessed by cavitation bubbles confirming disruption of Bruch’s membrane.
For anti-VEGF treatment, 11-week-old mice received bilateral intravitreal 
injections of 1 μl of a neutralizing antibody to mouse VEGF or of isotype IgG 
(50 ng, R&D Systems, Minneapolis, MN) immediately following laser injury 
to mimic current standard of care for human neovascular AMD. Seven days 
after laser treatment, mice were euthanized, and eyes were collected for the 
analysis of CNV volume and protein analysis.
Analysis of lesion volume in RPE/Choroid flat mounts
Eyes were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) for 2 hours after removal of the cornea and lens. Posterior 
eyecups of the RPE/choroid/sclera were dissected, and the vitreous was 
removed. Eyecups were incubated overnight at 4 °C with AlexaFluor 
647-conjugated Isolectin B4 (1:200, Invitrogen, Carlsbad, CA) to label invad-
ing choroidal vessels and anti-GFP antibody to label GFP in RPE cells (1:500, 
ABCAM, Cambridge, MA). After staining, the eyecups were flattened by cut-
ting radial incisions and flatmounted onto a microscope slide with vecta-
shield mounting medium (Vector Laboratories, Burlingame, CA) for confocal 
imaging. Flatmounts were imaged by taking optical Z-sections at 3 µm incre-
ments with a confocal microscope (FV1000, Olympus, Japan), and area for 
each Z-section was measured manually using Image J and summed to cre-
ate a volume. Only lesions with GFP-positive RPE cells were included for CNV 
volume analysis. Lesions with obvious hemorrhage or bridging CNV were 
excluded. Images were measured and confirmed by two masked reviewers.
Immunostaining in retinal cryosections
Eyes were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, PA) for 2 hours after removal of cornea and lens, followed by 
incubation with 10 to 30% sucrose overnight at 4 °C. Eye cups were then 
embedded in optimal cutting temperature (OCT) (Tissue Tek, Hatfield, PA) 
and sectioned. For immunofluorescence, cryosections (12 μm) were first 
incubated in 5% normal goat serum in PBS/0.1% TritonX-100 for 1 hour to 
block nonspecific binding of the primary antibody (see Table 1). Sections 
were incubated with rabbit anti-GFP (1:200) and RPE65 (1:100, ABCAM) 
overnight at 4 °C. After three washes in PBS, sections were incubated for 
1 hour with a 1:200 dilution of FITC-conjugated goat anti-rabbit secondary 
antibody (Invitrogen, Carlsbad, CA) for GFP and AlexaFluor 594-conjugated 
goat anti-mouse secondary antibody for RPE65. The sections were rinsed in 
PBS and mounted in DAPI-Fluoromount-G (SouthernBiotech, Birmingham, 
AL). Images were captured with an inverted microscope (OLYMPUS 1X81: 
Japan) at 20× magnification.
Cell culture and transduction of RPE with adenovirus and 
treatments
Human primary RPE (RPE) cells (Lonza, Walkersville, MD) were grown in 
RPE cell growth media (RtEGM, Lonza) with 2% FBS and used from passage 
3–5. Human primary choroidal endothelial cells (CECs) were isolated from 
donor eyes obtained from Utah Eye bank (Salt Lake City, UT) as previously 
described.41 CECs were grown in endothelial growth media (EGM2, Lonza) 
supplemented with 5% FBS and used from passage 1–5.
RPE cells were transduced with adenoviral constructs expressing GFP 
(Ad-GFP) or active Rap1a (Ad-63E). Forty-eight to 72 hours later when 90% of 
RPE cells were GFP positive, cells were incubated with recombinant human 
TNFα (10–20 ng/ml, R&D Systems), H2O2 (10 µmol/l) or PBS control for 5 
hours or overnight. Cells were then collected for western blots, coimmuno-
precipitation (CO-IP) and Rap1 activity assay.
Immunoprecipitation and Immunoblots
Please see Table 1 for a list of antibodies and catalog numbers used. RPE/
choroidal tissues and RPE cells were lysed in radio immunoprecipitation 
assay buffer (RIPA) (20 mmol/l Tris pH 7.4, 120 mmol/l NaCl, 0.5% sodium 
deoxycholic acid, 1% Triton X-100, 0.1% SDS, 10% glycerol) with protease 
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and phosphatase 
inhibitor orthovanadate (2 mmol/l, Sigma-Aldrich, St. Louis, MO). Lysates 
were centrifuged at 13,000 rpm for 5 minutes at 4 °C. Protein concentration 
in the supernatant was quantified by bicinchoninic acid assay (BCA) (Pierce, 
Rockford, IL). Thirty micrograms of protein from RPE/choroids were loaded 
into 4 to 12% NuPAGE Bis-Tris gels (Invitrogen, Carlsbad, CA), and transferred 
to a PVDF membrane (Invitrogen), incubated with antibodies to VEGF and 
phosphorylated ERK (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), and 
Rap1 and pan-cadherin (1:1,000, Cell signaling Technology, Danvers, MA) 
overnight at 4 °C.
For coimmunoprecipitation (CO-IP), total protein (500 µg in 500 ml) for 
each sample was incubated with antibody to β-catenin (1:100, Cell signaling 
Technology), IQGAP1 (1:100, BD Transduction Laboratories, Franklin Lakes, 
NJ) or pan-cadherin (1:100, Cell signaling Technology) by gently rocking at 
4 °C overnight with 10 µl of Dynabeads protein G (Invitrogen). The antibody/
protein/agarose complex was washed three times with RIPA buffer and resus-
pended in 2× sample buffer. Protein complex was separated by NuPAGE 4 to 
12% Bis-Tris Gels (Invitrogen) and transferred to a PVDF membrane and then 
incubated with antibodies to pan-cadherin (1:1,000) for CO-IP of β-catenin/
cadherin, β-catenin (1:1,000) for CO-IP of pan-cadherin/β-catenin or CO-IP 
of IQGAP1/β-catenin, or phosphoserine/threonine (1:1,000, BD Transduction 
Laboratories) for phosphorylated IQGAP1 overnight at 4 °C. All membranes 
were reprobed with anti-β-catenin, anti-IQGAP1 or anti-pan-cadherin to 
ensure equal β-catenin, IQGAP1 or pan-cadherin protein loading.
For Rap1 activity assay in RPE cells, 300 µg of protein from each treat-
ment was incubated with anti-GTP-Rap1 antibody (NewEast, Malvern, PA) 
and Dynabeads protein G at 4 °C overnight. Bead-bound active Rap1 was 
determined by western blots using a monoclonal antibody against Rap1 (BD 
Transduction Laboratories).
Densitometry analysis was done with the use of the software UN-SCAN-IT 
version 6.1 (Silk Scientific, Orem, UT).
ECIS assay and TER of RPE barrier integrity
Transepithelial resistance was measured by either the electric cell-substrate 
impedance sensing (ECIS)-Zθ system (Applied Biophysics, Troy, NY) or the 
EOVM2 system with the EndOhm electrode (World precision Instruments, 
Sarasota FL). For ECIS, an electrode culture assay was coated with attach-
ment factor protein (Invitrogen). RPE cells, 50,000 per well, were seeded in 
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complete media onto the electrode culture assay and monitored until a sta-
ble monolayer formed. Cells were then treated with 10 or 20 ng/ml human 
recombinant TNFα for 12 hours. Resistance across the monolayer was mea-
sured with 40 electrodes per well (1,000–2,000 cells) using the ECIS.
For TER measurement with the EOVM2 system, RPE cells were cultured 
in Transwells with 0.4 µm pores (Corning Incorporated, Corning, NY) until 
cells formed a monolayer and had TER measurements > 100 ohms.cm2. RPE 
cells were then transduced with adenoviral construct Ad-63E or control virus 
Ad-GFP. Forty-eight hours after virus transduction, RPE cells were incubated 
with human recombinant TNFα (20 ng/ml). TER of RPE monolayer was mea-
sured prior to addition of TNFα and 24 hours after incubation with TNFα. 
Data are representative of at least three independent experiments.
CEC transmigration assays
Transmigration of CECs across the RPE monolayer was measured as previ-
ously described.41 RPE cells were first plated onto the underside of Transwells 
having 8 µm pores (Corning Incorporated) until a monolayer was formed. 
The cells were then transduced with adenoviral construct Ad-63E or control 
virus Ad-GFP for 48 hours. CECs labeled with fluorescent dye (Vybrant Dil 
Cell-labeling solution; Invitrogen) were plated into the inserts with addi-
tion of recombinant TNFα (20 ng/ml) in the inserts and wells. Twenty-four 
hours after adding the CECs, migrated CECs were counted using fluorescent 
microscopy.
Statistical analysis
Significant differences between groups were determined by analysis of vari-
ance with post hoc protected Bonferroni Multiple Comparison Test. Results 
were displayed as Mean ± standard error of the mean. A P value of <0.05 was 
considered statistically significant. For animal studies, at least five individual 
mice and bilateral choroidal flat mounts were analyzed for CNV volume 
(n = 4 spots/eye), Micron IV imaging and optical coherence tomography. 
The results of the electroretinography analysis included an average of three 
eyes from three individual mice. Retinal sections for GFP staining and west-
ern blots of Rap1 protein were taken from five to seven different mice. For 
in vitro studies, each experimental condition included an n = 6–9 from three 
independent experiments.
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